Marilyn M Li

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4432225/publications.pdf Version: 2024-02-01



Μλαιίνη ΜΤι

#	Article	IF	CITATIONS
1	Standards and Guidelines for the Interpretation and Reporting of Sequence Variants in Cancer. Journal of Molecular Diagnostics, 2017, 19, 4-23.	2.8	1,267
2	Integrated Molecular and Clinical Analysis of 1,000 Pediatric Low-Grade Gliomas. Cancer Cell, 2020, 37, 569-583.e5.	16.8	244
3	Application of Next Generation Sequencing in Laboratory Medicine. Annals of Laboratory Medicine, 2021, 41, 25-43.	2.5	99
4	Clinical application of amplicon-based next-generation sequencing in cancer. Cancer Genetics, 2013, 206, 413-419.	0.4	98
5	Phase 2 study of the focal adhesion kinase inhibitor defactinib (VS-6063) in previously treated advanced KRAS mutant non-small cell lung cancer. Lung Cancer, 2020, 139, 60-67.	2.0	88
6	Clinical utility of custom-designed NGS panel testing in pediatric tumors. Genome Medicine, 2019, 11, 32.	8.2	79
7	Points to consider for reporting of germline variation in patients undergoing tumor testing: a statement of the American College of Medical Genetics and Genomics (ACMG). Genetics in Medicine, 2020, 22, 1142-1148.	2.4	59
8	Clinical efficacy of ruxolitinib and chemotherapy in a child with Philadelphia chromosome-like acute lymphoblastic leukemia with <i>GOLGA5-JAK2</i> fusion and induction failure. Haematologica, 2018, 103, e427-e431.	3.5	56
9	Genomic Analysis of Dysembryoplastic Neuroepithelial Tumor Spectrum Reveals a Diversity of Molecular Alterations Dysregulating the MAPK and PI3K/mTOR Pathways. Journal of Neuropathology and Experimental Neurology, 2019, 78, 1100-1111.	1.7	44
10	Development and Clinical Validation of a Large Fusion Gene Panel for Pediatric Cancers. Journal of Molecular Diagnostics, 2019, 21, 873-883.	2.8	41
11	Molecular Diagnosis of Mosaic Overgrowth Syndromes Using a Custom-Designed Next-Generation Sequencing Panel. Journal of Molecular Diagnostics, 2017, 19, 613-624.	2.8	36
12	Variant Interpretation for Cancer (VIC): a computational tool for assessing clinical impacts of somatic variants. Genome Medicine, 2019, 11, 53.	8.2	36
13	NTRK Fusions Identified in Pediatric Tumors: The Frequency, Fusion Partners, and Clinical Outcome. JCO Precision Oncology, 2021, 1, 204-214.	3.0	36
14	Fusion Oncogenes Are Associated With Increased Metastatic Capacity and Persistent Disease in Pediatric Thyroid Cancers. Journal of Clinical Oncology, 2022, 40, 1081-1090.	1.6	36
15	Variation in pre-PCR processing of FFPE samples leads to discrepancies in <i>BRAF</i> and <i>EGFR</i> mutation detection: a diagnostic RING trial. Journal of Clinical Pathology, 2015, 68, 111-118.	2.0	34
16	Overgrowth Syndromes Caused by Somatic Variants in the Phosphatidylinositol 3-Kinase/AKT/Mammalian Target of Rapamycin Pathway. Journal of Molecular Diagnostics, 2017, 19, 487-497.	2.8	33
17	A Rare <i>TP53</i> Mutation Predominant in Ashkenazi Jews Confers Risk of Multiple Cancers. Cancer Research, 2020, 80, 3732-3744.	0.9	32
18	p53 enables metabolic fitness and self-renewal of nephron progenitor cells. Development (Cambridge), 2015, 142, 1228-1241.	2.5	30

Marilyn M Li

#	Article	IF	CITATIONS
19	The spectrum of rare central nervous system (CNS) tumors with <i>EWSR1</i> â€nonâ€ETS fusions: experience from three pediatric institutions with review of the literature. Brain Pathology, 2021, 31, 70-83.	4.1	29
20	SETD2 mutations in primary central nervous system tumors. Acta Neuropathologica Communications, 2018, 6, 123.	5.2	27
21	AACR Project GENIE: 100,000 Cases and Beyond. Cancer Discovery, 2022, 12, 2044-2057.	9.4	27
22	Prenatal diagnosis of CLOVES syndrome confirmed by detection of a mosaic <i>PIK3CA</i> mutation in cultured amniocytes. American Journal of Medical Genetics, Part A, 2014, 164, 2633-2637.	1.2	26
23	Novel FGFR2-INA fusion identified in two low-grade mixed neuronal-glial tumors drives oncogenesis via MAPK and PI3K/mTOR pathway activation. Acta Neuropathologica, 2018, 136, 167-169.	7.7	20
24	Two novel RUNX1 mutations in a patient with congenital thrombocytopenia that evolved into a high grade myelodysplastic syndrome. Leukemia Research Reports, 2015, 4, 24-27.	0.4	17
25	Congenital tumors of the central nervous system: an institutional review of 64 cases with emphasis on tumors with unique histologic and molecular characteristics. Brain Pathology, 2021, 31, 45-60.	4.1	15
26	Rational drug combinations with CDK4/6 inhibitors in acute lymphoblastic leukemia. Haematologica, 2022, 107, 1746-1757.	3.5	14
27	CancerVar: An artificial intelligence–empowered platform for clinical interpretation of somatic mutations in cancer. Science Advances, 2022, 8, eabj1624.	10.3	14
28	A multicenter, cross-platform clinical validation study of cancer cytogenomic arrays. Cancer Genetics, 2015, 208, 525-536.	0.4	12
29	Sclerosing Epithelioid Fibrosarcoma of the Bone With Rare EWSR1-CREB3L3 Translocation Driving Upregulation of the PI3K/mTOR Signaling Pathway. Pediatric and Developmental Pathology, 2019, 22, 594-598.	1.0	12
30	Laboratory and Clinical Implications of Incidental and Secondary Germline Findings During Tumor Testing. Archives of Pathology and Laboratory Medicine, 2022, 146, 70-77.	2.5	11
31	BRAF fusions in pediatric histiocytic neoplasms define distinct therapeutic responsiveness to RAF paradox breakers. Pediatric Blood and Cancer, 2021, 68, e28933.	1.5	9
32	Breast adenocarcinoma recurring as small cell carcinoma in a patient with a germline BRCA2 mutation: clonal evolution unchecked. Experimental Hematology and Oncology, 2015, 4, 1.	5.0	8
33	Clinical Impact of Genomic Information in Pediatric Leukemia. Frontiers in Pediatrics, 2017, 5, 263.	1.9	7
34	Using Machine Learning to Identify True Somatic Variants from Next-Generation Sequencing. Clinical Chemistry, 2020, 66, 239-246.	3.2	7
35	Evolution of histomorphologic, cytogenetic, and genetic abnormalities in an untreated patient with MIRAGE syndrome. Cancer Genetics, 2020, 245, 42-48.	0.4	7
36	Clinical impact of genomic characterization of 15 patients with acute megakaryoblastic leukemia–related malignancies. Journal of Physical Education and Sports Management, 2021, 7, a005975.	1.2	7

MARILYN M LI

#	Article	IF	CITATIONS
37	Pediatric Somatic Tumor Sequencing Identifies Underlying Cancer Predisposition. JCO Precision Oncology, 2019, 3, 1-26.	3.0	6
38	Genomic characterization of a PPP1CB-ALK fusion with fusion gene amplification in a congenital glioblastoma. Cancer Genetics, 2021, 252-253, 37-42.	0.4	6
39	Multi-institutional study of the frequency, genomic landscape, and outcome of IDH-mutant glioma in pediatrics. Neuro-Oncology, 2023, 25, 199-210.	1.2	6
40	Using Cytogenetic Rearrangements for Cancer Prognosis and Treatment (Pharmacogenetics). Current Genetic Medicine Reports, 2013, 1, 99-112.	1.9	5
41	A Novel KMT2A-ARHGEF12 Fusion Gene Identified in a High-Grade B-cell Lymphoma. Cancer Genetics, 2020, 246-247, 41-43.	0.4	5
42	The oncogenic roles of NTRK fusions and methods of molecular diagnosis. Cancer Genetics, 2021, 258-259, 110-119.	0.4	5
43	Standardized evidence-based approach for assessment of oncogenic and clinical significance of NTRK fusions. Cancer Genetics, 2022, 264-265, 50-59.	0.4	5
44	Effects of epinephrine on angiogenesis-related gene expressions in cultured rat cardiomyocytes. Journal of Biomedical Research, 2016, 30, 380.	1.6	4
45	Novel ATXN1/ATXN1L::NUTM2A fusions identified in aggressive infant sarcomas with gene expression and methylation patterns similar to CIC-rearranged sarcoma. Acta Neuropathologica Communications, 2022, 10, .	5.2	4
46	Effects of Epinephrine on Inflammation-Related Gene Expressions in Cultured Rat Cardiomyocytes. Translational Perioperative and Pain Medicine, 2017, 2, 13-19.	0.1	3
47	Tiered Somatic Variant Classification Adoption Has Increased Worldwide With Some Practice Differences Based on Location and Institutional Setting. Archives of Pathology and Laboratory Medicine, 2022, 146, 822-832.	2.5	3
48	Mesenchymal PLAG1 Tumor With PCMTD1-PLAG1 Fusion in an Infant. American Journal of Dermatopathology, 2021, Publish Ahead of Print, 54-57.	0.6	2
49	Mammary-type Myofibroblastoma with Leiomyomatous Differentiation: A Rare Variant with Potential Pitfalls. International Journal of Surgical Pathology, 2022, 30, 200-206.	0.8	2
50	A germline PALB2 pathogenic variant identified in a pediatric high-grade glioma. Journal of Physical Education and Sports Management, 2020, 6, a005397.	1.2	2
51	Atypical teratoid rhabdoid tumor in a child with neurofibromatosis type 2: A novel dual diagnosis. Cancer Genetics, 2022, 262-263, 1-4.	0.4	2
52	A Novel TP53 Tandem Duplication in a Child with Li-Fraumeni Syndrome. Journal of Physical Education and Sports Management, 2022, , mcs.a006181.	1.2	2
53	Authors' Reply. Journal of Molecular Diagnostics, 2018, 20, 125-126.	2.8	1
54	KMT2Aâ€MAML2 rearrangement emerged and regressed during neuroblastoma therapy without leukemia after 12.8â€year followâ€up. Pediatric Blood and Cancer, 2022, 69, e29344.	1.5	1

Marilyn M Li

#	Article	IF	CITATIONS
55	Technical Standards and Guidelines for Use of Clinical Genomic Microarray Analysis in Hematopoietic and Other Neoplastic Disorders: A Draft From a Working Group of the American College of Medical Genetics Laboratory Quality Assurance Committee. Blood, 2011, 118, 4906-4906.	1.4	1
56	Clinical significance of serial tumor next generation sequencing (NGS) in 155 pediatric cancer patients Journal of Clinical Oncology, 2020, 38, e13666-e13666.	1.6	1
57	Recommendations for future extensions to the HGNC gene fusion nomenclature. Leukemia, 2021, 35, 3611-3612.	7.2	1
58	A Novel FBXO45-Gef-H1 Axis Controls Oncogenic Signaling in B-Cell Lymphoma. Blood, 2021, 138, 711-711.	1.4	1
59	EPID-11. A MULTI-INSTITUTIONAL COMPARATIVE ANALYSIS OF THE CLINICAL, GENOMIC, AND SURVIVAL CHARACTERISTICS OF PEDIATRIC, YOUNG ADULT AND OLDER ADULT PATIENTS WITH IDH-MUTANT GLIOMA. Neuro-Oncology, 2020, 22, ii80-ii81.	1.2	1
60	Neuroblastoma and cutaneous angiosarcoma in a child with PTEN hamartoma tumor syndrome. Pediatric Blood and Cancer, 2022, 69, e29656.	1.5	1
61	LGG-25. NOVEL FGFR2 FUSIONS DRIVE ONCOGENESIS VIA MAPK AND PI3K/mTOR PATHWAY ACTIVATION IN DYSEMBRYOPLASTIC NEUROEPITHELIAL TUMORS. Neuro-Oncology, 2018, 20, i109-i110.	1.2	0
62	LGG-07. CLINICAL FEATURES OF NON-CANONICAL MOLECULAR DRIVERS IN PLGG; AN UPDATE FORM THE INTERNATIONAL PLGG TASKFORCE. Neuro-Oncology, 2019, 21, ii100-ii100.	1.2	0
63	LGG-14. THE GENETIC LANDSCAPE OF DYSEMBRYOPLASTIC NEUROEPITHELIAL TUMORS. Neuro-Oncology, 2019, 21, ii102-ii102.	1.2	0
64	Abstract 449: A standard operating procedure for the curation of gene fusions. , 2021, , .		0
65	The efficacy of targeted next-generation sequencing for detection of clinically actionable mutations in cancer Journal of Clinical Oncology, 2012, 30, 10598-10598.	1.6	0
66	Identification of susceptibility loci in hereditary prostate cancer families using copy number variation and linkage analysis Journal of Clinical Oncology, 2015, 33, 232-232.	1.6	0
67	Effects of milrinone on inflammatory response-related gene expressions in cultured rat cardiomyocytes. Journal of Biomedical Research, 2019, 33, .	1.6	0
68	Whole genome SNP arrays for best practice for detection of diagnostic, prognostic and therapy related copy number changes and copy neutral-loss of heterozygosity across solid tumors and hematologic malignancies Journal of Clinical Oncology, 2020, 38, e15575-e15575.	1.6	0